EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bacterial amidohydrolases and modified 5-fluorocytidine compounds: Novel enzyme-prodrug pairs

Viktorija Preitakaitė iD, Povilas Barasa, Agota Aučynaitė, Gediminas Plakys, Martyna Koplūnaitė, Simona Zubavičiūtė, Rolandas Meškys

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0294696 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Viktorija Preitakaitė und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Microbiology and Biotechnology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Vilnius, Lithuania. Hauptthemen laut MEDLINE: Prodrugs, Colonic Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gene-directed enzyme prodrug therapy is an emerging strategy for cancer treatment based on the delivery of a gene that encodes an enzyme that is able to convert a prodrug into a potent cytotoxin exclusively in target cancer cells. However, it is limited by the lack of suitable enzyme variants and a scarce choice of chemical bonds that could be activated. Therefore, this study is aimed to determine the capability of bacterial amidohydrolases YqfB and D8_RL to activate novel prodrugs and the effect such system has on the viability of eukaryotic cancer cells. We have established cancer cell lines that stably express the bacterial amidohydrolase genes and selected several N 4 -acylated cytidine derivatives as potential prodrugs. A significant decrease in the viability of HCT116 human colon cancer cell lines expressing either the YqfB or the D8_RL was observed after exposure to the novel prodrugs. The data we acquired suggests that bacterial YqfB and D8_RL amidohydrolases, together with the modified cytidine-based prodrugs, may serve as a promising enzyme-prodrug system for gene-directed enzyme prodrug therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsColonic NeoplasmsAntineoplastic AgentsHumansAmidohydrolasesCytidine

Substanzen

ProdrugsAmidohydrolases5-fluorocytidineCytidineAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Molecular Microbiology and Biotechnology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
  • Department of Biological Models, Institute of Biochemistry, Life Sciences Center, Vilnius University, Vilnius, Lithuania.

ORCID-Profile: Viktorija Preitakaitė

Förderung

  • European Regional Development Fund

Zitieren

APA

Preitakaitė, V., Barasa, P., Aučynaitė, A., Plakys, G., Koplūnaitė, M., Zubavičiūtė, S., & Meškys, R. (2023). Bacterial amidohydrolases and modified 5-fluorocytidine compounds: Novel enzyme-prodrug pairs. PLOS ONE. https://doi.org/10.1371/journal.pone.0294696

Vancouver

Preitakaitė V, Barasa P, Aučynaitė A, Plakys G, Koplūnaitė M, Zubavičiūtė S, et al. Bacterial amidohydrolases and modified 5-fluorocytidine compounds: Novel enzyme-prodrug pairs. PLOS ONE. 2023. doi:10.1371/journal.pone.0294696

BibTeX
@article{Preitakait2023,
  author = {Preitakaitė, Viktorija and Barasa, Povilas and Aučynaitė, Agota and Plakys, Gediminas and Koplūnaitė, Martyna and Zubavičiūtė, Simona and Meškys, Rolandas},
  title = {Bacterial amidohydrolases and modified 5-fluorocytidine compounds: Novel enzyme-prodrug pairs},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0294696}
}
Kostenlos starten →